Ascendis Pharma A/S · ASND · FY2026 Q1 · Calendar Q2 2026

Ascendis Pharma tops Q1 EPS, YUVIWEL approved, full-year guidance maintained

Ascendis' first quarter showed improving profitability and balance-sheet strength: EUR 25 million operating profit, EUR 573 million cash, a $187.5 million PRV sale, and full redemption of convertible notes, alongside an EPS beat and FDA approval of YUVIWEL, its fourth approved product. Management's confidence rests on YORVIPATH dose escalation and patient growth (6,300+ U.S. patients, 35 countries), the YUVIWEL launch, and a deep TransCon pipeline. Against that, revenue of $284.9M missed the $308.9M consensus by about 8%, and the stock drifted roughly -14.5% after the report even as analysts kept targets near a $317 consensus versus the ~$226 current price. The bull case is supported by product breadth and execution, but tempered by the revenue miss, the subsequent negative drift, and unresolved regulatory, reimbursement, and free-drug-program items analysts flagged for coming quarters.

Why did ASND rise 4.3% after beating EPS estimates in FY2026 Q1?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNASDAQHealthcare $14.01B market cap
90quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.32 Consensus $0.19
EPS surprise +70.6% Reported versus consensus
Reported revenue $284.9M Consensus $308.9M
Revenue surprise -7.8% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +4.3% Event window
SPY move -0.3% Same window
Abnormal move +4.6% Stock minus SPY
Volume 1.8× Versus trailing sessions
Subsequent drift -14.5% Up to 20 sessions
ASNDSPY benchmark

Ask FN2 about ASND FY2026 Q1

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Ascendis reported FY2026 Q1 with EPS of $0.32 versus consensus of $0.1876 (+70.6% surprise), while revenue of $284.9M missed the $308.9M estimate (-7.8%). The FDA approved YUVIWEL, adding a fourth product. Management sold the priority review voucher for $187.5M, completed a NASDAQ direct listing with full redemption of convertible notes, and discontinued internal oncology development of TransCon IL-2 beta/gamma. Guidance was maintained. The stock rose 4.6% in the reaction window with 1.8x normal volume, then drifted -14.5% subsequently.

Guidance delta

Management maintained its guidance (sentiment: maintained); no numeric change was reported. The full-year outlook was described as upbeat, focused on continued commercial and clinical milestones.

Key takeaways

  • FDA approval of YUVIWEL adds a fourth product, bringing approved TransCon products to three across four rare endocrine indications.
  • Q1 revenue of EUR 247 million with operating profit of EUR 25 million and cash balance of EUR 573 million.
  • YORVIPATH now treats over 6,300 patients in the U.S. and is available in 35 countries with more than 2,700 prescribers.
  • Hypochondroplasia combination therapy showed triple efficacy versus monotherapy with high patient retention.
  • Sold its priority review voucher for $187.5 million in cash, completed a NASDAQ direct listing and fully redeemed its convertible notes.
  • Quarterly guidance was maintained.

Management priorities

  • Global expansion of YORVIPATH, including higher dosing to 60 mcg in the U.S. and new market launches.
  • International rollout of YUVIWEL via early access programs, with pursuit of EU label approval in Q4 2026.
  • Label expansion of YUVIWEL to infants and additional geographic regions.
  • Continue combination therapy development for hypochondroplasia and growth hormone indications.
  • Advance the TransCon semaglutide partnership with Novo Nordisk and move TransCon anti-VEGF toward clinic entry.

Follow ASND with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ASND REVENUE earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 actual $151M, None Q1 '24 actual $103M, None Q2 '24 estimate $113M Q2 '24 actual $39M, miss Q2 '25 estimate $233M Q2 '25 actual $186M, miss Q3 '25 estimate $303M Q3 '25 actual $250M, miss Q4 '25 estimate $292M Q4 '25 actual $345M, beat Q1 '26 estimate $309M Q1 '26 actual $285M, miss Q2 '26 estimate $377M Q2 '26 actual $387M, beat Q3 '26 estimate $409M Q3 '26 actual $419M, beat Q4 '26 estimate $406M Q1 '27 estimate $432M Q2 '27 estimate $482M Q3 '27 estimate $530M
Show less

Analyst Consensus ?

ConsensusBuy26 ratings
Bullish2492.3%
Neutral27.7%
Bearish00.0%

Analyst 52W Price Targets

$252.73Current
$136Low
$274.39Average
$352High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Citigroup Buy BuyMaintainOct 26, 2026
Cantor Fitzgerald Overweight OverweightMaintainSep 25, 2026
Raymond James Outperform Strong BuyDowngradeSep 15, 2026
Oppenheimer Outperform OutperformMaintainSep 2, 2026
Wedbush Outperform OutperformMaintainSep 1, 2026
Show 21 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $252.73. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
JefferiesKelly Shi$300$262.68 +18.7%Nov 17, 2026
RBC CapitalAnalyst unavailable$352$274.24 +39.3%Nov 13, 2026
KeyBancAnalyst unavailable$330$267.07 +30.6%Nov 13, 2026
Canaccord GenuityAnalyst unavailable$268$243.37 +6.0%Oct 26, 2026
CitigroupEric Joseph$330$243.37 +30.6%Oct 26, 2026
See 59 more

Track every rating change on ASND the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Historical context

All ASND earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the ASND recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-09-26T01:51:10.130169+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-26T01:51:10.127526+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-26. For educational purposes only; not investment advice.